Article
Osimertinib Treatment Was Unsuccessful for Lung Adenocarcinoma with G719S, S768I, and T790M Mutations.
Internal medicine (Tokyo, Japan) - 15 Dec 2018
Nasu Shingo, Shiroyama Takayuki, Morita Satomu, Takata So, Takada Hiromune, Masuhiro Kentaro, Tanaka Ayako, Morishita Naoko, Suzuki Hidekazu, Okamoto Norio, Hirashima Tomonori
Abstract excerpt
Epidermal growth factor receptor (EGFR) T790M mutations are the most frequent mechanism of resistance to first- and second-generation tyrosine kinase inhibitors, and osimertinib is an effective treatment for patients with both EGFR-activating mutations and T790M resistance mutations. We describe the case of a 68-year-old woman with lung adenocarcinoma with G719S, S768I, and T790M mutations in which osimertinib...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.